KILLION FREDERICK 4
4 · BARR PHARMACEUTICALS INC · Filed Dec 29, 2008
Insider Transaction Report
Form 4
KILLION FREDERICK
General Counsel
Transactions
- Disposition to Issuer
Stock Appreciation Rights
2008-12-23−15,000→ 0 totalExercise: $49.49From: 2008-11-11Exp: 2017-03-07→ Common Stock (15,000 underlying) - Disposition to Issuer
Common Stock
2008-12-23−11,589→ 0 total - Disposition to Issuer
Stock Options
2008-12-23−30,000→ 0 totalExercise: $35.01Exp: 2014-08-04→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Options
2008-12-23−62,500→ 0 totalExercise: $30.19Exp: 2012-03-01→ Common Stock (62,500 underlying) - Disposition to Issuer
Stock Options
2008-12-23−45,000→ 0 totalExercise: $43.34Exp: 2013-07-30→ Common Stock (45,000 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−30,000→ 0 totalExercise: $46.99Exp: 2015-07-27→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−45,000→ 0 totalExercise: $49.22From: 2008-11-11Exp: 2018-03-04→ Common Stock (45,000 underlying)
Footnotes (10)
- [F1]Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 7,268 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $462,401.10.
- [F10]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $777,600, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share.
- [F2]Option vested equally over a 3 year period from grant date
- [F3]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $2,269,581.25, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $30.1867 per share.
- [F4]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,042,200, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $43.34 per share.
- [F5]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $944,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share.
- [F6]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $585,300, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share.
- [F7]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $531,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share.
- [F8]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $255,150, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share.
- [F9]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $320,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $55.81 per share.